Skip to main content
Top
Published in: Annals of Hematology 10/2014

01-10-2014 | Original Article

Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre

Authors: Lijun Bai, Wei Xia, Kelly Wong, Cassandra Reid, Christopher Ward, Matthew Greenwood

Published in: Annals of Hematology | Issue 10/2014

Login to get access

Abstract

Engraftment outcomes following autologous transplantation correlate poorly to infused stem cell number. We evaluated 446 consecutive patients who underwent autologous transplantation at our centre between 2001 and 2012. The impact of pre-transplant and collection factors together with CD34+ dosing ranges on engraftment, hospital length of stay (LOS) and survival endpoints were assessed in order to identify factors which might be optimized to improve outcomes for patients undergoing autologous transplantation using haemopoietic progenitor cells–apheresis (HPC-A). Infused CD34+ cell dose correlated to platelet but not neutrophil recovery. Time to platelet engraftment was significantly delayed in those receiving low versus medium or high CD34+ doses. Non-remission status was associated with slower neutrophil and platelet recovery. Increasing neutrophil contamination of HPC-A was strongly associated with slower neutrophil recovery with infused neutrophil dose/kg recipient body weight ≥3 × 108/kg having a significant impact on time to neutrophil engraftment (p = 0.001). Higher neutrophil doses/kg in HPC-A were associated with days of granulocyte colony stimulation factor (G-CSF) use, HPC-A volumes >500 ml and higher NCC in HPC-A. High infused neutrophil dose/kg and age >65 years were associated with longer hospital LOS (p = 0.002 and 0.011 respectively). Only age, disease and disease status predicted disease-free survival (DFS) and overall survival (OS) in our cohort (p < 0.005). Non-relapse mortality was not affected by low dose of CD34+ (<2 × 106/kg). In conclusion, our study shows that CD34+ remains a useful and convenient marker for assessing haemotopoietic stem cell content and overall engraftment capacity post-transplant. Neutrophil contamination of HPC-A appears to be a key factor delaying neutrophil recovery. Steps to minimize the degree of neutrophil contamination in HPC-A product may be associated with more rapid neutrophil engraftment and reduced hospital LOS.
Literature
1.
go back to reference Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH (2002) Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 29:967–972PubMedCrossRef Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH (2002) Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 29:967–972PubMedCrossRef
2.
go back to reference Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W (1995) An analysis if engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961–3969PubMed Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W (1995) An analysis if engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961–3969PubMed
3.
go back to reference Siena S, Bregni M, Brando B, Belli N, Lansdorp PM, Bonadonna G, Gianni M (1991) Flow cytometry to estimate circulating hematopoietic progenitors for autologous transplantation: comparative analysis of different CD34 monoclonal antibodies. Haematologica 76:330–333PubMed Siena S, Bregni M, Brando B, Belli N, Lansdorp PM, Bonadonna G, Gianni M (1991) Flow cytometry to estimate circulating hematopoietic progenitors for autologous transplantation: comparative analysis of different CD34 monoclonal antibodies. Haematologica 76:330–333PubMed
4.
go back to reference Haas R, Möhle R, Frühauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787–3794PubMed Haas R, Möhle R, Frühauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787–3794PubMed
5.
go back to reference Kiss JE, Rybka WB, Winkelstein A, deMagalhaes-Silverman M, Lister J, D'Andrea P, Ball ED (1997) Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:303–310PubMedCrossRef Kiss JE, Rybka WB, Winkelstein A, deMagalhaes-Silverman M, Lister J, D'Andrea P, Ball ED (1997) Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:303–310PubMedCrossRef
6.
go back to reference Papadopoulos KP, Ayello J, Tugulea S, Heitjan DF, Williams C, Reiss RF, Reiss RF, Vahdat LT, Suciu-Foca N, Antman KH, Hesdorffer CS (1997) Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematother 6:61–68PubMedCrossRef Papadopoulos KP, Ayello J, Tugulea S, Heitjan DF, Williams C, Reiss RF, Reiss RF, Vahdat LT, Suciu-Foca N, Antman KH, Hesdorffer CS (1997) Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematother 6:61–68PubMedCrossRef
7.
go back to reference Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruuto T, Madrigal A, Johnsen HE, Quality assessment of haematopoietic stem cell grafting committee of European Blood and Marrow Transplantation Society (2013) Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transplant 19:1670–1676PubMedCrossRef Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruuto T, Madrigal A, Johnsen HE, Quality assessment of haematopoietic stem cell grafting committee of European Blood and Marrow Transplantation Society (2013) Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transplant 19:1670–1676PubMedCrossRef
8.
go back to reference Shpall EJ, Champlin R, Glaspy JA (1998) Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 4:84–92PubMedCrossRef Shpall EJ, Champlin R, Glaspy JA (1998) Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 4:84–92PubMedCrossRef
9.
go back to reference Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK (1994) Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol 22:1003–1010PubMed Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK (1994) Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol 22:1003–1010PubMed
10.
go back to reference Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D (2003) Validation of the single-platform ISHAGE method for CD34 (+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 5:55–65PubMedCrossRef Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D (2003) Validation of the single-platform ISHAGE method for CD34 (+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 5:55–65PubMedCrossRef
11.
go back to reference Sartor M, Antonenas V, Garvin F, Webb M, Bradstock KF (2005) Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant 36:199–204PubMedCrossRef Sartor M, Antonenas V, Garvin F, Webb M, Bradstock KF (2005) Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant 36:199–204PubMedCrossRef
12.
go back to reference Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547–2555PubMed Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547–2555PubMed
13.
go back to reference Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L, Masia CM, Centurioni R, Mancini S, Brunori M, Leoni P (1998) Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 83:329–337PubMed Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L, Masia CM, Centurioni R, Mancini S, Brunori M, Leoni P (1998) Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 83:329–337PubMed
14.
go back to reference Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontet C, Moullet I, Eljaafari-Corbin A, Neidhardt-Berard EM, Bouafia F, Coiffier B (1998) High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 9:3148–3155 Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontet C, Moullet I, Eljaafari-Corbin A, Neidhardt-Berard EM, Bouafia F, Coiffier B (1998) High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 9:3148–3155
15.
go back to reference Abrahamsen JF, Wentzel-Larsen T, Bruserud O (2004) Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg. Cytotherapy 6:356–362PubMedCrossRef Abrahamsen JF, Wentzel-Larsen T, Bruserud O (2004) Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg. Cytotherapy 6:356–362PubMedCrossRef
16.
go back to reference Jansen J, Thompson JM, Dugan MJ, Nolan P, Wiemann MC, Birhiray R, Henslee-Downey PJ, Akard LP (2002) Peripheral blood progenitor cell transplantation. Ther Apher 6:5–14PubMedCrossRef Jansen J, Thompson JM, Dugan MJ, Nolan P, Wiemann MC, Birhiray R, Henslee-Downey PJ, Akard LP (2002) Peripheral blood progenitor cell transplantation. Ther Apher 6:5–14PubMedCrossRef
17.
go back to reference Hicks C, Wong R, Manoharan A, Kwan YL (2007) Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Ann Hematol 86:591–598PubMedCrossRef Hicks C, Wong R, Manoharan A, Kwan YL (2007) Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Ann Hematol 86:591–598PubMedCrossRef
18.
go back to reference Lefrère F, Delarue R, Somme D, Levy V, Damaj G, Tu A, Porcher R, Audat F, Boulat C, Cavazzana-Calvo M, Buzyn A, Belanger C, Maillard N, Hermine O, Varet B (2002) High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion 42:443–450PubMedCrossRef Lefrère F, Delarue R, Somme D, Levy V, Damaj G, Tu A, Porcher R, Audat F, Boulat C, Cavazzana-Calvo M, Buzyn A, Belanger C, Maillard N, Hermine O, Varet B (2002) High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion 42:443–450PubMedCrossRef
19.
go back to reference Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R, Eades WC, Creer MH, Nolta JA (2006) Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 107:2162–2169PubMedCentralPubMedCrossRef Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R, Eades WC, Creer MH, Nolta JA (2006) Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 107:2162–2169PubMedCentralPubMedCrossRef
20.
go back to reference Lioznov MV, Freiberger P, Kröger N, Zander AR, Fehse B (2005) Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. Bone Marrow Transplant 35:909–914PubMedCrossRef Lioznov MV, Freiberger P, Kröger N, Zander AR, Fehse B (2005) Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. Bone Marrow Transplant 35:909–914PubMedCrossRef
21.
go back to reference Christ O, Lucke K, Imren S, Leung K, Hamilton M, Eaves A (2007) Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica 92:1165–1172PubMedCrossRef Christ O, Lucke K, Imren S, Leung K, Hamilton M, Eaves A (2007) Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica 92:1165–1172PubMedCrossRef
22.
go back to reference Foïs E, Desmartin M, Benhamida S, Xavier F, Vanneaux V, Rea D, Fermand J-P, Arnulf B, Mounier N, Ertault M, Lotz J-P, Galicier L, Raffoux E, Benbunan M, Marolleau J-P, Larghero J (2007) Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. Bone Marrow Transplant 40:831–835PubMedCrossRef Foïs E, Desmartin M, Benhamida S, Xavier F, Vanneaux V, Rea D, Fermand J-P, Arnulf B, Mounier N, Ertault M, Lotz J-P, Galicier L, Raffoux E, Benbunan M, Marolleau J-P, Larghero J (2007) Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. Bone Marrow Transplant 40:831–835PubMedCrossRef
23.
go back to reference Rowley SD (1992) Techniques of bone marrow and stem cells cryopreservation and storage. In: Sacher RA, Aubuchon JP (eds) Marrow transplantation: practice and technical aspects of stem cells reconstitution. American Association of Blood Banks, Bethesda, pp 105–127 Rowley SD (1992) Techniques of bone marrow and stem cells cryopreservation and storage. In: Sacher RA, Aubuchon JP (eds) Marrow transplantation: practice and technical aspects of stem cells reconstitution. American Association of Blood Banks, Bethesda, pp 105–127
24.
go back to reference Miller CB, Piantadosi S, Vogelsang GB, Marcellus DC, Grochow L, Kennedy MJ, Jones RJ (1996) Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 14:1327–1332PubMed Miller CB, Piantadosi S, Vogelsang GB, Marcellus DC, Grochow L, Kennedy MJ, Jones RJ (1996) Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 14:1327–1332PubMed
25.
go back to reference Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, Rambaldi A, Bosi A (2012) Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 47:342–351PubMedCentralPubMedCrossRef Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, Rambaldi A, Bosi A (2012) Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 47:342–351PubMedCentralPubMedCrossRef
26.
go back to reference Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM, Leonhardt M, Bradburn M, Okukenu E, Salam A, Matthews J, Cavenagh JD, Gupta RK, Lister TA (2000) Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 1:367–373PubMedCrossRef Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM, Leonhardt M, Bradburn M, Okukenu E, Salam A, Matthews J, Cavenagh JD, Gupta RK, Lister TA (2000) Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 1:367–373PubMedCrossRef
27.
go back to reference Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E (2004) Prediction of mobilisation failure in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 33:907–912PubMedCrossRef Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E (2004) Prediction of mobilisation failure in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 33:907–912PubMedCrossRef
28.
go back to reference Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ, Bridger G, Marulkar S, Hsu FJ, Dipersio JF (2011) Transplanted CD34+ cells dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with Non-Hodgkin Lymphoma or Multiple Myeloma. Biol Blood Marrow Transplant 17:1146–1153PubMedCrossRef Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ, Bridger G, Marulkar S, Hsu FJ, Dipersio JF (2011) Transplanted CD34+ cells dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with Non-Hodgkin Lymphoma or Multiple Myeloma. Biol Blood Marrow Transplant 17:1146–1153PubMedCrossRef
29.
go back to reference Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, de Witte T, Ljungman P, McDonald F, McGrath E, Passweg J, Peters C, Rocha V, Slaper-Cortenbach I, Sureda A, Tichelli A, Apperley J (2011) Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29:1980–1986PubMedCrossRef Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, de Witte T, Ljungman P, McDonald F, McGrath E, Passweg J, Peters C, Rocha V, Slaper-Cortenbach I, Sureda A, Tichelli A, Apperley J (2011) Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29:1980–1986PubMedCrossRef
Metadata
Title
Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre
Authors
Lijun Bai
Wei Xia
Kelly Wong
Cassandra Reid
Christopher Ward
Matthew Greenwood
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2112-2

Other articles of this Issue 10/2014

Annals of Hematology 10/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.